BREAST CANCER

This study tested a new hormone therapy (amcenestrant) combined with palbociclib against the standard letrozole plus palbociclib in over 1,000 people with ER+/HER2- advanced breast cancer who had not received prior treatment for advanced disease. The goal was to see if the new co…

This study looked at menopausal women over 50 with very small breast cancers (less than 10 mm). It compared standard surgery plus armpit lymph node removal versus surgery alone. The goal was to see if skipping lymph node removal could reduce side effects without affecting surviva…

This study tested a combination of two drugs—pembrolizumab (an immunotherapy) and mifepristone (a hormone blocker)—in people with advanced HER2-negative breast cancer. The goal was to see if the combination could shrink tumors. The study was stopped early after enrolling 24 parti…

This study tested a new radioactive drug, [225Ac]-FPI-1434, in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited. It involved 78 partic…

This study tested a combination of two oral drugs, BKM120 and lapatinib, in people with a specific type of advanced breast cancer (HER2-positive) that had stopped responding to the standard drug trastuzumab. The goal was to see if the combo was safe and could shrink tumors. The s…

This study tested the drug abemaciclib in 27 people with a specific, hard-to-treat form of advanced breast cancer (triple negative, retinoblastoma-positive). The goal was to see if the drug could shrink tumors. The trial was stopped early, so results are limited.

This study tested a combination of two drugs, abemaciclib and elacestrant, in women with a type of breast cancer (HR+/Her2-) that had spread to the brain. The goal was to see if the drugs could shrink brain tumors and control the disease. Only 5 people enrolled before the study w…

This study tested an experimental oral drug called amcenestrant in postmenopausal women with a certain type of advanced breast cancer (ER+/HER2-). The goal was to find safe doses and see if it worked alone or with other cancer drugs. The trial was terminated early, and results ar…

This study tested a new drug, amcenestrant, against an older drug, tamoxifen, in people with hormone receptor-positive early breast cancer who had to stop their initial hormone therapy due to side effects. The goal was to see if amcenestrant could better prevent the cancer from c…

This study tested a drug called neratinib, alone or with another drug (fulvestrant), in 21 people with a specific type of advanced breast cancer (HER2-positive and ER-positive). The goal was to see if the combination could slow cancer growth better than neratinib alone. The study…

This study tested two different doses of a new drug called amcenestrant against the standard drug letrozole in postmenopausal women with early-stage, hormone-receptor-positive breast cancer. The goal was to see if amcenestrant could better slow tumor growth before surgery. The st…

This early-stage study tested a combination of focused ultrasound and the immunotherapy drug pembrolizumab in 13 people with metastatic breast cancer. The goal was to see if the ultrasound could help the immune system better attack tumors. The study was stopped early, so results …

This early-stage trial tested a new drug called SAR443216 in 44 adults with advanced HER2-positive cancers (like breast, lung, or stomach cancer) that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study was termina…

This study tested a new drug, GDC-0084, combined with trastuzumab (Herceptin) in 17 people with HER2-positive breast cancer that had spread to the brain. The goal was to see if the combination could shrink brain tumors. The trial was terminated early, so results are limited.

This early-stage study tested a new drug called TAS2940 in 29 people with advanced solid tumors (like lung, breast, or brain cancer) that had certain genetic changes (EGFR or HER2). The goal was to find a safe dose and see if it could shrink tumors. The trial was stopped early, s…

This study tested a new drug (LY2780301) combined with standard chemotherapy (paclitaxel) in 68 people with advanced HER2-negative breast cancer. The goal was to find the safest dose and see if the combination could shrink tumors. The trial was terminated early, so final results …

This study aimed to compare two radiation methods—3D conformal radiation therapy and internal brachytherapy—given after breast-conserving surgery for early-stage breast cancer. The goal was to see which approach better kills remaining cancer cells while sparing healthy tissue. Ho…

This early-phase study tested a new drug (infigratinib) combined with tamoxifen for people with a specific advanced breast cancer that is hormone receptor-positive, HER2-negative, and has changes in the FGFR gene. The main goal was to find a safe dose by monitoring side effects. …

This early-stage trial tested a new drug combination (TQB3912, fulvestrant, and TQB3616) in people with a common type of advanced breast cancer (HR-positive, HER2-negative). The goal was to find the safest dose and see if the drugs could shrink tumors or delay cancer growth. Howe…

This study tested a new drug called NUV-868, alone or combined with other cancer drugs (olaparib or enzalutamide), in people with advanced solid tumors like ovarian, pancreatic, prostate, or breast cancer. The main goals were to check safety and find the right dose. The study was…

This study looked at whether using mammograms and breast MRIs can help doctors decide if a patient with an early, non-invasive breast cancer called DCIS can be treated with a single dose of radiation during surgery. The goal was to see if this approach would reduce the need for a…

This study tested a new drug called TAK-500, given alone or with another drug (pembrolizumab), in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The study was stopped early…

This study tested whether a special MRI technique called DWIBS can better identify suspicious breast lesions found on mammograms and ultrasounds. Researchers aimed to see if it could tell cancerous from non-cancerous growths and possibly reduce false alarms that lead to unnecessa…

This study tested a new, high-speed 3D ultrasound method called acoustic angiography to improve imaging of breast and thyroid cancers. It planned to enroll 45 people, including healthy volunteers and patients scheduled for biopsies. The goal was to see if this technique could bet…

This study tested a new, fast, and low-cost MRI method to screen for breast cancer in women with dense breasts or moderate risk. The goal was to see if this MRI could find cancers earlier and more accurately than standard mammograms. The study was stopped early, but it aimed to r…

This study tested a special fluorescent dye (PD G 506 A) and camera system to help surgeons see leftover breast cancer cells in real-time during breast-conserving surgery. The goal was to help surgeons remove all the cancer in one operation, reducing the need for patients to have…

This study looked at whether giving radiation to the brain early could prevent cancer from spreading there in people with HER2-positive breast cancer that had already spread to other organs. All participants were receiving trastuzumab (Herceptin) plus chemotherapy. The study was …

This study tested whether a technique called axillary reverse mapping with lympho-venous bypass could prevent or reduce arm swelling (lymphedema) in people having lymph nodes removed for breast cancer or melanoma. The approach aimed to preserve or reroute the arm's lymph drainage…

This study tested a program to improve quality of life for young African American women who finished treatment for early- or late-stage breast cancer. About 27 women took part in either the program or a comparison group. The goal was to see if the program helped with physical, me…

This study looked at whether a mechanical stimulation technique could reduce pain and improve shoulder function better than standard massages in women who had a total mastectomy and lymph node removal for breast cancer. About 80 participants were planned, but the study was stoppe…

This study tested a digital tool that appears on the lock screen of an Android phone to encourage physical activity in cancer survivors. Participants used the app and wore a Fitbit for 3 months, with follow-up at 6 months. The goal was to see if the app could increase activity an…

This study tested a smartphone app called medidux™ to see if it could help track and reduce serious side effects in people with HER2-positive breast cancer undergoing chemotherapy and targeted therapy. The trial planned to enroll 196 adults but was stopped early. The app was desi…

This study tested whether continuously infusing a local anesthetic (ropivacaine) into the surgical wound after mastectomy reduces pain and speeds recovery compared to a placebo. It involved 59 women with breast cancer. The goal was to improve pain control at rest and during movem…

This study looked at whether wearing a chest bandage after mastectomy could reduce the number of times doctors need to drain fluid buildup (seroma). It included 60 women who had already needed at least two large drainages. Half wore a bandage plus got drainage, the other half onl…

This study tested a special cream (Dermaprazole) to prevent skin irritation caused by radiation therapy in women who had a mastectomy for breast cancer. The goal was to see if the cream was safe and could reduce skin redness, peeling, and swelling. Only 3 people took part before …

This study tested a special donor nipple graft for women who had breast reconstruction after breast cancer. The goal was to see if the graft healed safely and how long it took. Only 6 people took part before the study was stopped early.

This study tested if applying tranexamic acid (TXA) directly to the surgical site during breast reconstruction after mastectomy could reduce bleeding (hematomas) and fluid collections (seromas). These complications can delay healing and cancer treatments. The study enrolled 23 wo…

This study tested whether the sleep medication suvorexant (20 mg) could help breast cancer survivors who have trouble sleeping. Five postmenopausal women who had finished cancer treatment and were taking hormone therapy were enrolled. The trial was stopped early, so results are l…

This study looked at 289 people with early-onset breast, ovarian, colorectal, or pediatric cancers, plus those with multiple tumors. Researchers used a special test to check 200 genes for inherited mutations that standard tests might miss. The goal was to better understand why th…

This study looked at whether giving a short course of immunotherapy (atezolizumab, alone or with other drugs) before standard treatment could boost the immune system's attack on early-stage breast cancer. It involved 33 people with triple-negative or HER2-positive breast cancer. …

This study aimed to test a simpler consent process to compare three standard chemotherapy plans for triple-negative breast cancer (TNBC). Only 2 people took part before the study was stopped early. The goal was to see if this new approach could help doctors learn which treatment …

This study looked at 42 women with advanced breast cancer who had chemotherapy before surgery. Researchers compared three imaging tests—PET-CT, ultrasound, and MRI—to see which one best measures leftover tumor size. The goal was to help doctors choose the right surgery and avoid …

This study aimed to understand how chemotherapy affects the ability to have children in young women (ages 18-37) with breast cancer. Researchers measured changes in ovarian reserve (egg supply) over two years. The goal was to provide better fertility information and help personal…

This study aimed to find genetic and protein changes in breast cancer tumors to better understand the disease. Researchers planned to study 749 adults with breast cancer, but the study was stopped early. The goal was to learn how these molecular changes relate to patient outcomes…

This study looked at whether taking high doses of vitamin D could change certain genes in breast cancer tumors, and if a woman's weight affected those changes. Researchers planned to compare normal-weight and overweight women with breast cancer, giving some a standard dose and ot…

This study aimed to see how one round of chemotherapy affects the muscles of women with breast cancer. Researchers compared three different drug combinations (paclitaxel alone, with trastuzumab, or with carboplatin) by taking small muscle samples and measuring strength and body c…

This study created a registry for people who survived cancer as young adults (ages 18-39). Researchers wanted to understand their levels of depression, anxiety, social support, and financial stress. Participants filled out online surveys every 6 to 12 months. The registry also he…

This study aimed to track heart function changes in breast cancer patients receiving chemotherapy (epirubicin-cyclophosphamide and paclitaxel). Researchers used detailed heart imaging to detect early signs of damage, hoping to find ways to prevent long-term heart problems. Only 2…

This study aimed to see if postmenopausal women with higher body fat respond differently to standard doses of aromatase inhibitors (anastrozole or letrozole) compared to women with lower body fat. About 42 women with hormone-sensitive breast cancer were planned to participate, bu…

This study aimed to see if using an electronic system to track symptoms could improve quality of life for people with early-stage breast or colorectal cancer receiving chemotherapy. Only 8 participants were enrolled before the trial was stopped early. The main goal was to measure…

This study looked at why some breast cancer cells, called cancer stem cells, survive chemotherapy and cause the cancer to come back. Researchers collected tumor and blood samples from 56 women before, during, and after chemotherapy to find the genes and processes that help these …

This study looked at whether early, personalized support could help women with breast cancer return to work better than standard care. It involved 128 women who had surgery and chemotherapy. The study was terminated early, so results are limited.